Renal Cancer - Results from #760

Cuproptosis related gene PDHB is identified as a biomarker inversely associated with the progression of clear cell renal cell carcinoma. August 30, 2023

Impact of First Line Antiangiogenic Therapy Duration on Nivolumab Outcome in Metastatic Renal Cell Carcinoma Patients Treated in the GETUG-AFU 26 NIVOREN. August 29, 2023

Characterization of papillary and clear cell renal cell carcinoma through imaging mass cytometry reveals distinct immunologic profiles. August 29, 2023

A protocol for the development of core outcome sets for effectiveness trials and clinical audits in renal cell cancer (R-COS). August 29, 2023

Assessing the impact of lymphovascular invasion on overall survival in surgically treated renal cell carcinoma patients: A nationwide cohort analysis. August 28, 2023

Patient-specific simulations and navigation systems for partial nephrectomy. August 28, 2023

Merck Announces WELIREG® (belzutifan) Phase 3 LITESPARK-005 Trial Met Primary Endpoint of Progression-Free Survival in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma August 25, 2023

Identification of an endogenous retroviral signature to predict anti-PD1 response in advanced clear cell renal cell carcinoma: an integrated analysis of three clinical trials. August 25, 2023

Giant Renal Cell Carcinoma (RCC): A Case Report of Delayed Diagnosis and Management. August 25, 2023

Performance of a Cell-Free DNA-Based Multi-cancer Detection Test in Individuals Presenting With Symptoms Suspicious for Cancers. August 24, 2023

Immune dysfunction revealed by digital spatial profiling of immuno-oncology markers in progressive stages of renal cell carcinoma and in brain metastases. August 23, 2023

Predictors for complication in renal cancer surgery: a national register study. August 23, 2023

Machine learning-based on cytotoxic T lymphocyte evasion gene develops a novel signature to predict prognosis and immunotherapy responses for kidney renal clear cell carcinoma patients. August 23, 2023

Perioperative and oncological outcomes of robotic-assisted laparoscopic partial nephrectomy for cystic and solid renal masses: Evidence from controlled trials. August 23, 2023

Robot-assisted Simple Enucleation Versus Standard Robot-assisted Partial Nephrectomy for Low- or Intermediate-complexity, Clinical T1 Renal Tumors: A Randomized Controlled Noninferiority Trial. August 22, 2023

A novel necroptosis-related long noncoding RNA model for predicting clinical features, immune characteristics, and therapeutic response in clear cell renal cell carcinoma. August 22, 2023

Efficacy and safety evaluation of immunotherapy combined with targeted therapy as second-line treatment in patients with metastatic non-clear cell renal cell carcinoma. August 21, 2023

Predictive factors for pentafecta achievement in robot-assisted partial nephrectomy for intermediate highly complex RENAL tumors (RENAL score ≥ 7). August 21, 2023

Localized Non-Metastatic Sarcomatoid Renal Cell Carcinoma: A 31 Year Externally Verified Study. August 18, 2023

Patient-Reported Outcomes in KEYNOTE-564: Adjuvant Pembrolizumab Versus Placebo for Renal Cell Carcinoma. August 18, 2023

Page 39 of 456